Bilastine as a Potential Treatment in Allergic Rhinitis
Abstract
Background
Allergic rhinitis is a very frequent disease. H1 antihistamines have been used for treatment of allergic rhinitis for more than 5 decades. They differ in chemical structure, pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects.
Methods
We performed a detailed analysis of all available publications concerning the new H1-antihistamine bilasitine.
Results
Bilastine, a piperidine derivative, is a novel potent H1 antihistamine. It is at least as potent as cetirizine or fexofenadine in in vitro studies. In animal studies it demonstrates dose-dependent antihistaminic and antiallergic effects. In humans its metabolism is not affected by age, gender or renal function but may be affected by coadministration of P glycoprotein inhibitors. Efficacy of bilastine in therapy of allergic rhinitis patients has been documented in several large controlled clinical trials showing bilastine being at least as effective as cetirizine or desloratadine. No significant suppressive effect on central nervous system could be demonstrated when bilastine was used in the recommended doses.
Conclusion
Bilastine is a novel H1 antihistamine with anti-allergic properties which is highly effective in the treatment of symptoms of allergic rhinitis. It has a favorable pharmacokinetic and pharmacodynamic profile and is generally well tolerated.
Get full access to this article
View all access and purchase options for this article.
References
1. Settipane R.A., and Schwindt C. Chapter 15: Allergic rhinitis. Am J Rhinol Allergy 27(suppl): S52–S55, 2013.
2. Meltzer E.O., Blaiss M.S., Nacleiro R.M.et al. Burden of allergic rhinitis: Allergies in America, Latin America and Asia-Pacific adult surveys. Allergy Asthma Proc 33: S113–141, 2012.
3. Kakumanu S., Glass C., and Craig T. Poor sleep and daytime somnolence in allergic rhinitis: Significance of nasal congestion. Am J Respir Med 1: 195–200, 2002.
4. De la Hoz Caballer B., Rodríguez M., Fraj J.et al. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: The cross-sectional study to evaluate work productivity in allergic rhinitis compared with other common diseases (CAPRI) study. Am J Rhinol Allergy 26: 390–394, 2012.
5. Thompson A.K., Juniper E., and Meltzer E.O. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85: 338–347, 2000.
6. Leynaert B., Neukirch F., Demoly P.et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 106(suppl 5): S201–S205, 2001.
7. Bousquet J., van Cauwenberge P., and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl 5): S147–S334, 2001.
8. Bachert C. The role of histamine in allergic disease: Re-appraisal of its inflammatory potential. Allergy 57: 287–296, 2002.
9. Corcóstegui R., Labeaga L., Innerárity A.et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Drugs R D 6: 371–384, 2005.
10. Corcóstegui R., Labeaga L., Innerárity A.et al. In vivo pharmacological characterization of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 7: 219–231, 2006.
11. Gonzalo A., Lucero M., and Orjales A. Preclinical pharmacokinetics of bilastine, a new antihistamine drug, in rats and dogs. AAPS J 2007.
12. Ganza A., Gonzalo A., Lucero M.L., and Orjales A. Toxicokinetics of bilastine in animals: The effects of the dose and route of administration. Toxicol Lett 180(suppl): S70, 2008.
13. Mumford R., Allan L., Hoey R.et al. The disposition, metabolism and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. Drug Metab Rev 39(suppl I): 200–201, 2007.
14. Gonzalo A., and Lucero M.L. Identification of processes involved in bilastine bioavailability in rats. Drug metab Rev 40(suppl I): 42–43, 2008.
15. Lucero M.L., Orjales A., and Morag N. In vitro hepatic metabolism of [14C]-bilastine. Drug Metab Rev 39(suppl I): 114, 2007.
16. Roupe K., Sologuren A., Crean C., and Valiente R. The pharmacokinetics of bilastine after single and 14 days once daily administration. Basic Clin Pharmacol Toxicol 101(suppl 1): 148, 2007.
17. Roupe K., Sologuren A., Crean C., and Valiente R. Effects of age and gender on the pharmacokinetics and pharmacodynamics of bilastine. J Clin Pharmacol 47: 1198, 2007.
18. Lasseter K.C., Sologuren A., La Noce A., and Dilzer S.C. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clin Drug Investig 33: 665–673, 2013.
19. Sologuren A., Crean C., Veliente R., and McLeverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol 101(suppl 1): 148–149, 2007.
20. Crean C., Valiente R., Sologuren A., and McLaverty D. Effect of grapefruit juice on the pharmacokinetics of bilastine. J Clin Pharmacol 47: 1198, 2007.
21. Sologuren A., Valiente R., Crean C., and McLaverty D. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 47: 1198, 2007.
22. García-Gea C., Martínez-Colomer J., Antonijoan R.M.et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 28: 675–685, 2008.
23. Bachert C., Kuna P., Sanquer F.et al; The Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 64: 158–165, 2009.
24. Kuna P., Bachert C., Nowacki Z.et al; The Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study. Clin Exp Allergy 39: 1338–1347, 2009.
25. Horak F., Zieglmayer P., Zieglmayer R., and Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 59: 391–398, 2010.
26. Sastre J., Mullol A., Valero A., and Valiente R; Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 28: 121–130, 2012.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: July 1, 2014
Issue published: July/August 2014
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in American Journal of Rhinology & Allergy.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 198
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 8
- Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis...
- Features of the modern antihistamines use in the treatment of allergic...
- Actual antihistamine therapy
- Antihistamines in the treatment of allergic rhinitis
- Sex differences in the pharmacology of itch therapies—a narrative revi...
- Modern aspects of treatment of allergic rhinitis
- Bilastine: new insight into antihistamine treatment
- Editorial: Blending Medical and Surgical Therapies to Optimize Patient...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
